Krzysztof Krzemieniecki

Assessment of knowledge about cervical cancer and its prevention among female students aged 17-26 years

OBJECTIVE To assess knowledge about cervical cancer and its primary and secondary prevention, and identify the sources of information about the disease among female high school and university students in Krakow, Poland. STUDY DESIGN This study was based on a questionnaire consisting of 64 questions, divided into six parts: personal data, general knowledge about cervical cancer, estimation of risk factors, knowledge about primary prevention, knowledge about secondary prevention, and information sources. Data were collected from students aged 17-26 years over a 3-month period in 2011 and 2012. RESULTS Four hundred women living in Krakow or its vicinity were included in the study. Nearly all respondents (98.5%) had heard of cervical cancer, 89.4% were aware of the risk of death associated with cervical cancer, and 44.8% believed that the disease could affect them in the future. The interviewees considered genetics and family history to be the most important risk factors, followed by infection with human papillomavirus (HPV) and having multiple sex partners. Most (91.5%) respondents had not been vaccinated against HPV, 47.9% did not know where to go to get vaccinated, and 30.1% were unaware of vaccination as a prevention method. Most (91.5%) respondents were aware of cytological screening, and 86.5% thought that they should have it done in the future. Women who had not heard of cytological screening were more likely to be unaware of cervical cancer than women who had heard about cytological screening (odds ratio 0.24, 95% confidence interval 0.11-0.49, p=0.0001). The Internet, television and newspapers were reported to be the main sources of information about the disease. CONCLUSIONS General awareness of cervical cancer among young women in Poland is insufficient. HPV infection is not considered to be the major aetiological factor. A relatively high percentage of women in this study had never heard of the HPV vaccine as a way of preventing cervical cancer. Knowledge about cytological screening, however, appears to be much better.

Validation of the Polish Version of the EORTC QLQ-C30 and the QLQ-OG25 for the Assessment of Health-Related Quality of Life in Patients with Esophagi-Gastric Cancer

The aim of this study was to validate the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire Core 30 (QLQ-C30) and its esophagi-gastric module (QLQ-OG25) in their Polish language versions. Translation of the QLQ-OG25 was done according to EORTC guidelines. Each of the 98 patients filled out the two EORTC questionnaires and a personal questionnaire. Reliability and validity test were performed and patients’ comments were analyzed. The Polish version of the EORTC QLQ-C30 and the QLQ-OG25 are reliable and valid tools for measuring health-related quality of life in patients with esophagi-gastric cancer.

Targeted therapy in advanced colorectal cancer: more data, more questions.

Colorectal cancer (CRC) remains the third most common malignancy and the third leading cause of cancer death worldwide. The introduction of new chemotherapeutics and monoclonal antibodies into the treatment protocols for advanced CRC has significantly improved the outcomes. Nowadays, oncologists have a wide range of agents to choose for the treatment of advanced CRC; however, their optimal administration remains unclear. This article presents recently published data from the trials evaluating the use of monoclonal antibodies in advanced CRC with a particular emphasis on the predictive and prognostic factors of response to targeted therapy. The results from the CRYSTAL and OPUS studies indicate that the benefit from the addition of cetuximab to first-line chemotherapy is restricted to patients with the wild-type KRAS gene, with the best outcomes observed among those with unmutated forms of both the KRAS and BRAF genes. However, that has not been confirmed in the preliminary data from the COIN trial. Panitumumab has been shown to improve the outcomes when combined with first-line and second-line chemotherapy, but again mostly in patients with wild-type KRAS. The article also describes the detrimental effect of combined anti-vascular endothelial growth factor and anti-epidermal growth factor blockade in the first-line setting observed in the PACCE and the CAIRO-2 trials. Finally, results from the BRiTE registry indicating benefit from continuation of bevacizumab after progression on the first-line regimen are discussed in the context of maintenance therapy. Modern treatment for advanced CRC is based not only on clinical and anatomo-pathological but also molecular tumour characteristics. Our knowledge of the optimal administration of monoclonal antibodies in advanced CRC has extended significantly over the last few years; however, there are still many questions that have to be answered in future trials.

Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study

Aims and background Clinical practice shows significant differences in treatment outcomes and toxicity of sunitinib across patients. This retrospective study assessed early predictive markers for progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) treated with sunitinib in the first-line setting. Methods We evaluated 28 patients with stage IV clear cell RCC (with good or intermediate MSKCC risk prognosis) treated at the Department of Oncology, University Hospital, Cracow between 2008 and 2013. Data included demographic profiles, adverse events during first cycle of therapy, treatment delays, and treatment outcomes. Sunitinib was administered on a standard schedule (50 mg/day, 4 weeks on, 2 weeks off). PFS values were estimated with the Kaplan-Meier method and compared using the log-rank test; we identified independent PFS predictors using multiple Cox regression models. Results PFS was significantly longer in patients who experienced at least 1 adverse event after the first cycle of sunitinib (median 17.6 months vs. 5.6; p = 0.006). Hypertension and hand-foot syndrome were significantly correlated with longer PFS (29.3 vs. 6.0 months; p = 0.002, and not reached vs. 9.8 months; p = 0.002, respectively). We observed a similar (though not significant) tendency for neutropenia (17.5 vs. 8.4 months; p = 0.055). In multiple Cox regression, hypertension was the only individual independent predictor of PFS, but the co-occurrence of any 2 or 3 sunitinib-induced adverse events also predicted longer survival. Conclusions Although small, our study suggests that hypertension and hand-foot syndrome predict longer PFS in patients with clear cell RCC treated with sunitinib. The co-occurrence of 2 or more side effects seems also a significant predictor of longer survival. Larger studies are warranted to confirm the correlation between co-occurring side effects and PFS.

Creating and field-testing the questionnaire for the assessment of knowledge about cervical cancer and its prevention among schoolgirls and female students

Objective The aim of this study was to develop and validate a questionnaire used to assess the level of general knowledge about cervical cancer, its primary and secondary prevention, and to identify sources of information about the disease among schoolgirls and female students. Methods The questionnaire development process was divided into four phases: generation of issues; construction of a provisional questionnaire; testing of the provisional questionnaire for acceptability and relevance; field-testing, which aimed at ensuring reliability and validity of the questionnaire. Field-testing included 305 respondents of high school female Caucasian students, who filled out the final version of the questionnaire. Results After phase 1, a list of 65 issues concerning knowledge about cervical cancer and its prevention was generated. Of 305, 155 were schoolgirls (mean age±SD, 17.8±0.5) and 150 were female students (mean age±SD, 21.7±1.8). The Cronbach alpha coefficient for the whole questionnaire was 0.71 (range for specific questionnaire sections, 0.60 to 0.81). Test-retest reliability ranged from 0.89 to 0.94. Conclusion The Cervical-Cancer-Knowledge-Prevention-64 has been successfully developed to measure the level of knowledge about cervical cancer. The results confirm the validity, reliability and applicability of the created questionnaire.

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

SummaryBisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.ZusammenfassungIn der Vergangenheit waren Bisphosphonate die einzige Möglichkeit zur Vermeidung und Behandlung von Skelettkomplikationen bei ossär metastasierten Patienten. Neuere klinische Studien zeigen, dass Denosumab bei der Vermeidung von Skelettkomplikationen möglicherweise einen zusätzlichen Nutzen gegenüber Zoledronat aufweist. Für beide Wirkstoffklassen wurden vergleichbare Verträglichkeitsprofile berichtet, wobei es sowohl mit Bisphosphonaten, als auch mit Denosumab zu seltenen Fällen von Kieferosteonekrosen kam. Bisphosphonate wiesen eine höhere Inzidenz an Nierenschäden auf, Denosumab zeigte eine höhere Rate an Hypokalzämien. Basierend auf der aktuellen Evidenz, geben weder die American Society of Clinical Oncology (ASCO), noch die National Comprehensive Cancer Network (NCCN) Leitlinien zur Behandlung von ossär metastasierten Patienten eine Empfehlung zugunsten einer der beiden Wirkstoffklassen ab. Denosumab könnte jedoch gegenüber den Bisphosphonaten einen Vorteil bei Patienten mit chronischer Niereninsuffizienz bieten. Künftige Forschung und wachsende klinische Erfahrung wird die Evidenzgrundlage für klinische Entscheidungen in der Praxis entsprechend vertiefen.

The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer—Further observations from the IMPACT solid study

OBJECTIVE To investigate the use and impact of granulocyte colony-stimulating factors (G-CSF) on chemotherapy delivery and neutropenia management in breast cancer in a clinical practice setting. METHODS IMPACT Solid was an international, prospective observational study in patients with a physician-assessed febrile neutropenia (FN) risk of ≥20%. This analysis focused on stages I-III breast cancer patients who received a standard chemotherapy regimen for which the FN risk was published. Chemotherapy delivery and neutropenia-related outcomes were reported according to the FN risk of the regimen and intent of G-CSF use. RESULTS 690 patients received a standard chemotherapy regimen; 483 received the textbook dose/schedule with a majority of these regimens (84%) having a FN risk ≥10%. Patients receiving a regimen with a FN risk ≥10% were younger with better performance status than those receiving a regimen with a FN risk <10%. Patients who received higher-risk regimens were more likely to receive G-CSF primary prophylaxis (48% vs 22%), complete their planned chemotherapy (97% vs 88%) and achieve relative dose intensity ≥85% (93% vs 86%) than those receiving lower-risk regimens. Most first FN events (56%) occurred in cycles not supported with G-CSF primary prophylaxis. CONCLUSION Physicians generally recommend standard adjuvant chemotherapy regimens and were more likely to follow G-CSF guidelines for younger, good performance status patients in the curative setting, and often modify standard regimens in more compromised patients. However, G-CSF support is not optimal, indicated by G-CSF primary prophylaxis use in <50% of high-risk patients and observation of FN without G-CSF support.

Acupuncture: could it become everyday practice in oncology?

Acupuncture is a complementary and alternative medical treatment (CAM) which is increasingly used in the care of cancer patients. Traditionally derived from Chinese medicine, nowadays it is becoming a part of evidence-based oncology. The use of acupuncture in these patients has been recommended by the American Cancer Society (ACS) for the treatment of side effects associated with conventional cancer therapy and cancer-related ailments. A growing body of evidence supports the use of acupuncture in the treatment of cancer-induced pain and chemotherapy-related nausea and vomiting. Also other indications, such as xerostomia, fatigue, hot flashes, anxiety and peripheral neuropathy, are being constantly evaluated. This article summarizes the most important discoveries related to the possible usefulness of this method in contemporary oncology. Emphasis is placed on the results of randomized controlled trials with an adequate level of evidence. However, explanation of the mechanisms responsible for these effects requires confirmation in further studies with an adequate level of evidence. In future, acupuncture may become an interesting and valuable addition to conventional medicine.

Main influencing factors and health-related quality of life issues in patients with oesophago-gastric cancer – as measured by EORTC tools

Aim of the study To assess influencing factors and main health-related quality of life (HRQoL) issues in patients with cancers of the oesophago-gastric region using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire Core 30 (QLQ-C30) and its oesophago-gastric module (QLQ-OG25). Material and methods Patients were qualified for this study based on the histological confirmation of oesophageal, oesophago-gastric or gastric cancers. Each patient filled out the Polish version of the EORTC QLQ-C30, the QLQ-OG25 module and a personal questionnaire. Patients were divided into groups based on gender, age, treatment intention, tumour localization, working status and level of education. Results Our study included 112 patients – 39 women (35%) and 73 men (mean age ± SD; 60.2 ±10.9). Thirty-five patients (31.3%) completed the questionnaires twice. Eighty-four (75%) patients had gastric cancer (GC), twenty-six (23.2%) oesophageal cancer (OC) and two (1.8%) cancer of the oesophago-gastric junction (OGJC). Eighty (71.4%) patients underwent surgical treatment prior to either chemo-, radio- or chemoradiotherapy. The Global Health Status scale of the QLQ-C30 inversely correlated with all the other QLQ-C30 and QLQ-OG25 symptom scales (r = –0.26 to –0.61; p < 0.05). Conclusions The main HRQoL problems of Polish OC, OGJC and GC patients are fatigue, insomnia, anxiety, and appetite and weight loss. Older age, receiving palliative treatment, having gastric cancer, being on retirement and having lower education are factors associated with higher symptom scores (worse symptoms) and thus poorer HRQoL.

Acute treatment with doxorubicin induced neurochemical impairment of the function of dopamine system in rat brain structures.

BACKGROUND The clinical studies have shown that chemotherapy may impair cognitive functions especially in the patients treated for breast cancer. It should be mention that only few studies have made use of animals to investigate the effects of chemotherapy on the brain function. Doxorubicin (Adriamycin) is an anthracycline antibiotic commonly used for chemotherapy of breast cancer. METHODS This study examined the effect of doxorubicin (1.5 and 3.0mg/kg ip) after acute administration on the levels of dopamine, noradrenaline, serotonin and their metabolites in the rat brain structures connected with cognition and psychiatric disorders. RESULTS The data indicate that doxorubicin produced a significant and specific for the dopamine system inhibition of its activity in the investigated structures connected with the fall of dopamine concentration (decrease from 25 to 30% in the frontal cortex; from 30 to 60% in the hippocampus and about 20% of the control in the striatum, p<0.05) and its extraneuronal metabolite, 3-MT (from 35% in the frontal cortex to 60% in the hippocampus of the control level, p<0.01). However, doxorubicin did not affect others monoaminergic transmitters in the brain: noradrenaline and serotonin. CONCLUSION Summing up, these data indicate that a single injection of doxorubicin produced a clear and significant inhibition of dopamine system activity in all investigated structures with the strongest effect in the hippocampus what may lead to the disturbances of the cognitive functions at the patients treated for cancer. Moreover, such treatment did not significantly affect others monoaminergic transmitters such as noradrenaline and serotonin.